Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2124549 | European Journal of Cancer | 2011 | 9 Pages |
Abstract
In this prospective study of breast cancer patients treated with trastuzumab-radiotherapy with, in most cases, anthracycline-based chemotherapy and IMC irradiation, both the rate of abnormal LVEF after concurrent trastuzumab-radiotherapy and the skin toxicity were deemed acceptable. Further follow-up is needed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lucas Caussa, Youlia M. Kirova, Nathalie Gault, Jean-Yves Pierga, Alexia Savignoni, François Campana, Rémi Dendale, Alain Fourquet, Marc A. Bollet,